USANA HEALTH SCIENCES INC Q4 FY2025 earnings call

Andrew Masuda welcomes everyone to the call. Kevin Guest returns as CEO, outlining priorities: strengthen global brand positioning, enhance customer and brand partner experience, reinvigorate global sales momentum, advance product innovation pipeline, improve operational efficiencies, and execute with accountability. Doug Hekking provides color on fiscal 2026 outlook, noting net sales growth midpoint of 4%, inventory increases due to Rise Wellness and Hiya, and effective tax rate guidance range. Kevin Guest closes by stating USANA is in a strong position with core business showing stabilization and new initiatives like Hiya and Rise Wellness.

Consolidated net sales outlook for fiscal 2026 is for growth of 4% at the midpoint. Rise Wellness expected to be approximately breakeven in fiscal 2026. Effective tax rate guidance for fiscal 2026 ranges between 55% and 60%.

Q: Discusses better-than-expected results, revenue and EPS guidance ranges, macro environment impact, seasonality of core nutritional business, cost realignment, technology initiatives.

A: G. Hekking and others discuss Rise Wellness and Hiya growth, seasonality in core business, cost savings from realignment, and technology plans.

Q: Asks about integrating technology into consumer health management journey.

A: Kevin Guest and Kathryn Armstrong talk about technology utilization for personalized nutrition and scientific integrity in related devices.